Literature DB >> 8071869

Physostigmine and galanthamine: probes for a novel binding site on the alpha 4 beta 2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells.

E F Pereira1, M Alkondon, S Reinhardt, A Maelicke, X Peng, J Lindstrom, P Whiting, E X Albuquerque.   

Abstract

In the present study, we demonstrated that the chicken alpha 4 beta 2 neuronal nicotinic receptor stably expressed in transfected mouse fibroblasts (M10 cells) can be activated via the acetylcholine-binding site or via a site that is distinct from that for acetylcholine and recognizes physostigmine and galanthamine as agonists. In outside-out patches excised from dexamethasone-induced M10 cells, (+)-anatoxin-a, physostigmine and galanthamine (each at 1 microM) activated single channels with conductances of 18 and 30 pS. Dihydro-beta-erythroidine (1-30 nM), but not the nicotinic receptor-specific monoclonal antibody FK1, reduced the frequency of channels activated by anatoxin (1 microM). On the other hand, the frequency of channel activity induced by physostigmine (1 microM) was unaffected by dihydro-beta-erythroidine and was markedly decreased by FK1. In uninduced M10 cells and in dexamethasone-treated untransfected fibroblasts, we observed that physostigmine, galanthamine and nicotinic agonists did not evoke whole-cell or single-channel currents. Also, neither [3H]L-nicotine nor FK1 was able to bind to uninduced M10 cells. In dexamethasone-induced M10 cells, the nicotinic agonists acetylcholine, anatoxin, 1,1-dimethyl-4-phenylpiperazinium, (-)-nicotine, and cytisine (each at 100 microM) activated whole-cell currents that showed a marked inward rectification and were sensitive to blockade by dihydro-beta-erythroidine (100 nM). However, neither galanthamine nor physostigmine could evoke whole-cell currents in cells that were responsive to nicotinic agonists. Other effects of physostigmine and galanthamine on the nicotinic receptor that outweight the agonist properties of these compounds could account for their inability to evoke whole-cell currents.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8071869

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  20 in total

1.  Cholinesterase inhibitors ameliorate spatial learning deficits in rats following hypobaric hypoxia.

Authors:  Sangu Muthuraju; Panchanan Maiti; Preeti Solanki; Alpesh Kumar Sharma; Shashi Bala Singh; Dipti Prasad; Govindasamy Ilavazhagan
Journal:  Exp Brain Res       Date:  2010-05-11       Impact factor: 1.972

Review 2.  Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.

Authors:  A Nordberg; A L Svensson
Journal:  Drug Saf       Date:  1998-12       Impact factor: 5.606

3.  Chronic exposure to nicotine upregulates the human (alpha)4((beta)2 nicotinic acetylcholine receptor function.

Authors:  B Buisson; D Bertrand
Journal:  J Neurosci       Date:  2001-03-15       Impact factor: 6.167

4.  Subunit-dependent modulation of neuronal nicotinic receptors by zinc.

Authors:  B Hsiao; D Dweck; C W Luetje
Journal:  J Neurosci       Date:  2001-03-15       Impact factor: 6.167

Review 5.  Nicotine aversion: Neurobiological mechanisms and relevance to tobacco dependence vulnerability.

Authors:  Christie D Fowler; Paul J Kenny
Journal:  Neuropharmacology       Date:  2013-09-18       Impact factor: 5.250

6.  Effect of galantamine on the human alpha7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity.

Authors:  Laura Texidó; Esteve Ros; Mireia Martín-Satué; Susana López; Jordi Aleu; Jordi Marsal; Carles Solsona
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

7.  Young and older good learners have higher levels of brain nicotinic receptor binding.

Authors:  Diana S Woodruff-Pak; Melissa A Lehr; Jian-Guo Li; Lee-Yuan Liu-Chen
Journal:  Neurobiol Aging       Date:  2008-10-23       Impact factor: 4.673

Review 8.  Nicotinic agonists, antagonists, and modulators from natural sources.

Authors:  John W Daly
Journal:  Cell Mol Neurobiol       Date:  2005-06       Impact factor: 5.046

9.  Morantel allosterically enhances channel gating of neuronal nicotinic acetylcholine alpha 3 beta 2 receptors.

Authors:  Tse-Yu Wu; Caleb M Smith; Steven M Sine; Mark M Levandoski
Journal:  Mol Pharmacol       Date:  2008-05-05       Impact factor: 4.436

Review 10.  Clinical pharmacokinetics of galantamine.

Authors:  Martin R Farlow
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.